MIRABEGRON,SOLIFENACIN

The U.S. FDA approved Mirabegron + Solifenacin on 28 June 2012 for managing symptoms of overactive bladder. Mirabegron is a Beta 3-adrenoceptor agonist and Solifenacin is a muscarinic receptor antagonist. Together, they work to increase bladder capacity and reduce urinary urgency and frequency in patients with overactive bladder.

Mirabegron + Solifenacin treats symptoms associated with an overactive bladder, such as urgency incontinence (inability to control bladder emptying), sudden urination urges, and increased urinary frequency.

Take the Mirabegron + Solifenacin as your physician advises. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the tablet if your doctor advises you to stop.

The most common side effects of Mirabegron + Solifenacin are increased heart rate, nausea, constipation, diarrhea, dizziness, and urinary tract infection. Serious side effects while taking Mirabegron + Solifenacin are irregular heartbeat, sudden or throbbing headache, angioedema (swelling of the face, mouth, or throat), and elevated blood pressure.

Mirabegron + Solifenacin should not be taken if you have allergies to Mirabegron, Solifenacin, or if you have high uncontrolled blood pressure. Before starting the treatment, inform your doctor if you have trouble emptying your bladder (urinary retention) or if you are taking specific medications for HIV, fungal or bacterial infections, or anticholinergic medicine. Avoid taking this medicine if you have a severe stomach or bowel condition such as toxic megacolon, muscle disease (myasthenia gravis), or glaucoma with progressive vision loss. It is recommended not to consume this medicine if you are undergoing kidney dialysis or if you have severe liver disease.

Notify your doctor if you have liver or kidney problems. Your doctor may adjust your dose in such conditions. Also, inform your doctor if you have any heart conditions, such as abnormal ECG (QT prolongation) or taking medications that may cause it. This medicine is not advised to use in children under 18 years old. Inform your doctor if you are pregnant, planning to get pregnant, or think you may be pregnant or breastfeeding. Report to your doctor if you have constipation, stomach tear (hiatus hernia), heartburn, or nervous disorder (autonomic neuropathy).

Patients with hepatic, cardiac, or renal disorders should use Mirabegron + Solifenacin with caution and must inform their doctor of all underlying medical conditions and concurrent medications. This combination is contraindicated in patients with lactose intolerance. Do not discontinue Mirabegron + Solifenacin without medical advice. If a dose is missed, do not take a double dose to compensate. Report any serious adverse effects to your doctor immediately. Your doctor will determine whether dose adjustment is necessary based on your clinical response and tolerability. Consult your doctor for additional information regarding this medication.

Astellas Pharma Ltd, Electronic Medicines Compendium (EMC), [Revised on December 2022] [Accessed on 6th June 2023], Mirabegron + Solifenacin-TAB PL-Patient United Kingdom (Great Britain) en - TW366830 (medicines.org.uk) Astellas Pharma US, Inc; [Revised on March 2021] [Accessed on 6th June 2023], label (fda.gov) Astellas Pharma Ltd, Electronic medicines compendium (EMC), [Revised on Dec 2022] [ Accessed on 20th June 2023], https://www.medicines.org.uk/emc/files/pil.5559.pdf GlaxoSmithKline, US Food and Drug Administration, [Revised on April 2010] [ Accessed on 20th June 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021518s008lbl.pdf Goodman & Gilman'sGilman's, The Pharmacological Basis of Therapeutics, Muscarinic receptor agonists and antagonists, 12th edition, 2011, 231. J. Goddard, A.N. Turner, Kidney and urinary tract disease, Davidson’s Principles and Practice of Medicine, 22nd Edition, 2014, 461-523.